| 孟永斌,潘 波,程思谟,翟笑枫,朱晓俊,凌昌全.解毒颗粒联合阿帕替尼治疗中晚期肝癌的回顾性研究[J].,2020,(13):2467-2470 |
| 解毒颗粒联合阿帕替尼治疗中晚期肝癌的回顾性研究 |
| Retrospective Study of Jiedu Granules Combined with Apatinib in the Treatment of Advanced Liver Cancer |
| 投稿时间：2020-02-04 修订日期：2020-02-28 |
| DOI：10.13241/j.cnki.pmb.2020.13.013 |
| 中文关键词: 肝癌 解毒颗粒 阿帕替尼 炎症因子 中晚期 疗效 |
| 英文关键词: Liver cancer Jiedu granule Apatinib Inflammatory factors Advanced Curative effect |
| 基金项目:上海市卫生计生委科研资助项目(20182020) |
|
| 摘要点击次数: 767 |
| 全文下载次数: 412 |
| 中文摘要: |
| 摘要 目的：评估解毒颗粒联合阿帕替尼治疗中晚期肝癌患者的疗效及其不良反应。方法：对2018年12月至2019年6月收治于海军军医大学第一附属医院口服解毒颗粒联合阿帕替尼的27例肝癌患者的临床资料进行回顾性研究。无法切除或复发的中晚期肝癌患者被纳入研究，给予解毒颗粒联合阿帕替尼治疗直至疾病进展或不可耐受其毒副反应，随访观察治疗效果、生存期、炎症因子指标及不良反应。结果：治疗后完全缓解（CR）4例（14.81%），部分缓解（PR）4例（14.81%），稳定（SD）8例（29.63%），进展（PD）11名患者（40.74%），疾病控制率（DCR）为59.26%（16/27），客观缓解率（ORR）为29.63%（8/27）。中位无进展生存期（PFS）为3.630个月，中位总生存期（OS）为13.667个月。常见的不良反应是高血压59.26%（16/27）、蛋白尿59.26%（16/27）、腹泻74.07%（20/27）以及手足综合征62.96%（17/27）。治疗后炎症因子指标中C反应蛋白、白介素2水平下降，存在统计学差异（P<0.05）。结论：解毒颗粒联合阿帕替尼治疗中晚期肝癌安全、有效，可降低患者炎症反应，不良反应可耐受。 |
| 英文摘要: |
| ABSTRACT Objective: To evaluate the efficacy and adverse reactions of Jiedu Granules combined with apatinib in patients with advanced liver cancer. Methods: A retrospective study was conducted on the clinical data of 27 patients with liver cancer who were treated in the First Affiliated Hospital of Naval Military Medical University from December 2018 to June 2019 with oral Jiedu granules and apatinib. Patients with unresectable or recurrent liver cancer were included in the study, Jiedu granules were combined with apatinib until the disease progressed or its toxic and side effects could not be tolerated, follow-up observation was made on the treatment effect, survival time, disease progression time, inflammatory factor indexs and adverse reactions. Results: 4 patients (14.81%) with complete remission (CR), 4 patients (14.81%) with partial remission (PR), 8 patients (29.63%) with stable (SD), 11 patients (40.74%) with progression (PD), disease control rate (DCR) was 59.26% (16/27), the objective response rate (ORR) was 29.63% (8/27). The median progression-free survival (PFS) was 3.630 months, the median overall survival (OS) was 13.667 months. The most common adverse reactions were hypertension 59.26% (16/27), proteinuria 59.26% (16/27), diarrhea 74.07% (20/27), and hand-foot syndrome 62.96% (17/27). C-reactive protein and interleukin 2 levels were decreased in the inflammatory factor indexs after treatment, there were statistical differences(P<0.05). Conclusion: Jiedu granules combined with apatinib are safe and effective for treat advanced liver cancer and can reduce the patient's inflammatory response, the adverse reactions can be tolerated. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
